JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sun, B.
Right arrow Articles by Kambayashi, J.-I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, B.
Right arrow Articles by Kambayashi, J.-I.

Vol. 299, Issue 2, 652-658, November 2001

OPC-28326, a Selective Femoral Vasodilator, Is an alpha 2C-Adrenoceptor-Selective Antagonist

Bing Sun, Simon Lockyer, Jess Li, Ruoyan Chen, Masuhiro Yoshitake and Jun-Ichi Kambayashi

Vascular Biology and Circulation, Maryland Research Laboratories, Otsuka Maryland Research Institute, Rockville, Maryland

OPC-28326 has been reported to selectively increase femoral blood flow in open-chest dogs and autoperfused canine femoral artery preparations. Preliminary data indicated that OPC-28326 has a high affinity at the alpha 2-adrenoceptor. In the present study, we tested OPC-28326 in isoflurane anesthetized rats at a dose of 3 mg/kg of body weight, given intraduodenally. OPC-28326 significantly increased femoral blood flow, by 44.7 ± 13.8%, 45 min after drug administration, whereas carotid blood flow increased by only 3.6 ± 5.5% (n = 6). Chinese hamster ovary cell lines overexpressing rat alpha 2D-, alpha 2B-, or alpha 2C-adrenoceptor were established. These cells also coexpress luciferase, driven by cAMP elevation. In radioligand binding assays using cell membrane preparations, OPC-28326 dose dependently competed with [3H]RX821002 binding, with calculated Ki values of 3840 ± 887, 633 ± 46, and 13.7 ± 1.9 nM on alpha 2D-, alpha 2B-, and alpha 2C-adrenoceptor, respectively. A similar affinity and rank order of potency were also found for OPC-28326 on the alpha 2-subtypes using epinephrine as agonist in luciferase assays. No agonistic effect of OPC-28326 was detected on any of the alpha 2-adrenoceptors. Finally, in situ hybridization performed on skeletal muscle tissue sections collected from rat hind limb (musculus gastrocnemius) demonstrated a high level expression of alpha 2C in the vascular tissues. Thus, the abundance of alpha 2C in the skeletal muscle may account for the selective effect of OPC-28326 in increasing femoral blood flow.


0022-3565/01/2992-0652$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.